此外，9月19日凌晨，美国联邦储备委员会宣布，将联邦基金利率目标区间下调50个基点。美联储巴尔金近日表示，如果经济按预期发展，今年还有两次降息25个基点是“合理的路径”。中信建投指出，随着美联储自2020年3月以来首次宣布降息，全球流动性边际改善，医药行业投融资景气度有望快速恢复，具备估值优势。随着降息周期开启，医药投融资有望逐步恢复，研发需求的提升将有利于具备全球竞争力的CXO龙头及细分领域龙头。CRO concept stocks had the highest gains in early trading. As of press release, Pharmaceuticals (02359) rose 7.32% to HK$64.55; Tiger Pharmaceuticals (03347) rose 7.02% to HK$51.05; Pharmaceuticals (02269) rose 6.72% to HK$20; and Kanglong Chemical (03759) rose 6.67% to HK$16.96.
The Zhitong Finance App learned that CRO concept stocks had the highest increase in early trading. As of press release, Pharmaceuticals (02359) rose 7.32% to HK$64.55; Tiger Pharmaceuticals (03347) rose 7.02% to HK$51.05; Pharmaceuticals (02269) rose 6.72% to HK$20; Kanglong Chemical (03759) rose 6.67% to HK$16.96.
According to the news, on September 19, the US Senate Armed Services Committee announced the Senate version of the FY2025 National Defense Authorization Act (NDAA), which does not include proposals related to the “Biosafety Act.” BOC International believes that the US Biosafety Act has not been included in the NDAA, which means that biosafety legislation has been further delayed, and the possibility of a separate law during the year has declined. At the same time, the latest version of Act S.3558 did not include Pharmacovigilance. According to the US legislative process, the bank believes that other companies mentioned may also eventually be removed from the list.
Furthermore, in the early morning of September 19, the US Federal Reserve announced that it would lower the federal funds rate target range by 50 basis points. Federal Reserve Bank Barkin recently said that if the economy develops as expected, cutting interest rates by 25 basis points twice this year is a “reasonable path.” CITIC Construction Investment pointed out that as the Federal Reserve announced interest rate cuts for the first time since March 2020 and global liquidity improved marginally, the investment and financing boom in the pharmaceutical industry is expected to recover rapidly and has a valuation advantage. As the interest rate cut cycle begins, pharmaceutical investment and financing are expected to gradually resume, and the increase in R&D demand will benefit CXO leaders and sector leaders with global competitiveness.